Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
Rhea-AI Summary
Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company, has announced it will release its first quarter 2025 financial results and corporate highlights on Monday, May 5, 2025. The announcement will be made after U.S. financial markets close.
The company, based in Cambridge, Massachusetts, specializes in transforming drug discovery through a combination of:
- Leading-edge computational technologies
- Experimental technologies
This upcoming financial disclosure represents a standard quarterly reporting event for the precision medicine developer, providing stakeholders with insights into the company's financial performance and operational progress for Q1 2025.
Positive
- Company maintains status as a clinical-stage precision medicine company
- Demonstrates continued operation of their unique drug discovery platform combining computational and experimental technologies
Negative
- None.
News Market Reaction – RLAY
On the day this news was published, RLAY declined 4.91%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Monday, May 5, 2025.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Pete Rahmer
prahmer@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
When will Relay Therapeutics (RLAY) release Q1 2025 earnings?
What will Relay Therapeutics Q1 2025 earnings report include?
Where is Relay Therapeutics (RLAY) headquartered?
What type of company is Relay Therapeutics (RLAY)?
Which stock exchange is Relay Therapeutics listed on?
